Publicité
Publicité

ATRA

ATRA logo

Atara Biotherapeutics, Inc

13.79
USD
Sponsorisé
-3.65
-20.94%
09 janv., 15:59 UTC -5
Fermé
exchange

Après-marché

13.69

-0.10
-0.71%

ATRA Rapports sur les bénéfices

Ratio de surprise positive

ATRA a dépassé 19 des 40 dernières estimations.

48%

Prochain rapport

Date du prochain rapport
05 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.72M
/
-$0.44
Variation implicite de Q3 25 (Revenue/ EPS)
-21.09%
/
+37.50%
Variation implicite de Q4 24 (Revenue/ EPS)
-91.68%
/
-63.03%

Atara Biotherapeutics, Inc earnings per share and revenue

On 12 nov. 2025, ATRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.87 USD, resulting in a 63.52% surprise. Revenue reached 3.45 million, compared to an expected 1.43 million, with a 142.21% difference. The market reacted with a -0.72% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analystes forecast an EPS of -0.44 USD, with revenue projected to reach 2.72 million USD, implying an hausse of 37.50% EPS, and baisse of -21.09% in Revenue from the last quarter.
FAQ
For Q3 2025, Atara Biotherapeutics, Inc reported EPS of -$0.32, beating estimates by 63.52%, and revenue of $3.45M, 142.21% above expectations.
The stock price moved down -0.72%, changed from $12.56 before the earnings release to $12.47 the day after.
The next earning report is scheduled for 05 mars 2026.
Based on 6 analystes, Atara Biotherapeutics, Inc is expected to report EPS of -$0.44 and revenue of $2.72M for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité